SOURCE: DUSA PHARMACEUTICALS, INC.

DUSA Pharmaceuticals, Inc.

May 05, 2009 06:30 ET

DUSA Hits the Road With The Skin Cancer Foundation to Raise Awareness of Skin Cancer

The Road to Healthy Skin Tour Provides Free Skin Exams Across the U.S.

WILMINGTON, MA--(Marketwire - May 5, 2009) - DUSA Pharmaceuticals, Inc.® (NASDAQ: DUSA) is pleased to announce that they are a supporting sponsor of The Skin Cancer Foundation's 2009 Road to Healthy Skin Tour. The tour, which officially hits the road in May, offers free full body skin exams and informational materials to raise awareness about the importance of early detection, prevention and treatment of skin cancer and pre-cancers such as actinic keratoses (AKs). More than 10 million Americans have AKs and while most lesions remain benign, a study has shown that up to 10 percent develop into squamous cell carcinoma (SCC), the second most common form of skin cancer, within an average of two years.

"We are delighted about the opportunity to work with The Skin Cancer Foundation and volunteering dermatologists to bring the general public information regarding the most common form of cancer in the U.S.," said Bob Doman, DUSA's Chief Executive Officer. "The tour is a unique program that provides people with the tools they need to follow up with their dermatologists regularly to maintain good skin health. Patient education, empowerment and the treatment provided by dermatologists are the driving forces behind early detection and prevention of skin cancer."

The tour will make 80 stops in 25 cities including New York, Boston, Los Angeles and San Francisco. At each stop, board-certified dermatologists will perform full body skin cancer screenings in a mobile screening center. All exams will follow the guidelines set by the American Academy of Dermatology (AAD). In addition, all participants will have access to the traveling resource center that further explains at-home detection strategies and recommendations for maintaining healthy skin and treatment options for AKs and skin cancers.

About DUSA Pharmaceuticals

DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan® photodynamic therapy (PDT) technology platform, and complementary dermatology products. Levulan® PDT is currently approved for the treatment of Grade 1 and 2 actinic keratoses of the face and scalp. DUSA also markets other dermatology products, including ClindaReach®. DUSA is researching the use of Levulan® PDT to prevent AKs and squamous cell carcinomas in immunosuppressed solid organ transplant recipients and is supporting research related to oral leukoplakia in collaboration with National Institutes of Health (NIH). DUSA is based in Wilmington, Mass. Please visit our Web site at www.dusapharma.com.

About The Skin Cancer Foundation

Now celebrating its 30th year, The Skin Cancer Foundation is committed to educating the public and medical professionals about sun safety. As leaders in the fight against skin cancer, the Foundation is the only global organization solely devoted to the prevention, detection and treatment of the world's most common cancer. The mission of the Foundation is to decrease the incidence of skin cancer through public and professional education and research. To learn more about the Foundation and its programs, visit www.skincancer.org.